natgillin/translations-raw huggingface dataset:
Patients should be reassessed regularly by their prescriber/healthcare provider so that the dose of Budesonide/Formoterol Teva remains optimal. 
Zdravnik , ki predpisuje zdravilo, mora bolnike redno ocenjevati, tako da odmerek zdravila Budezonid/formoterol Teva ostane optimalen.
Hypokalaemia Hyperglycaemia 
Presnovne in prehranske motnje hipokaliemija hiperglikemija
Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only. 
Zdravilo Budezonid/formoterol Teva je indicirano izključno pri odraslih, starih 18 let in več.
• Mild sore throat, coughing and a hoarse voice. 
• blago vnetje žrela, kašelj in hripavost,
This medicine should not be used in children or adolescents under the age of 18 years. 
Otroci in mladostniki, mlajši od 18 let, tega zdravila ne smejo uporabljati.
Budesonide/Formoterol Teva 320 micrograms/9 micrograms inhalation powder 
Budezonid/formoterol Teva 320 mikrogramov/9 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva 160 micrograms / 4.5 micrograms inhalation powder 
Budezonid/formoterol Teva 160 mikrogramov/4,5 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva 320 mcg/9 mcg inhalation powder budesonide/formoterol fumarate dihydrate 
Budezonid/formoterol Teva 320 mcg/9 mcg prašek za inhaliranje budezonid/formoterolijev fumarat dihidrat za inhaliranje
Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland Unit 27/35, IDA Industrial Park, Cork Road, Waterford, Ireland Teva Pharmaceuticals Europe B.V., Swensweg 5, 2031 GA Haarlem, Netherlands Teva Operations Sp. Z o.o ul, Mogilska 80; 31-546 Krakow, Poland. 
Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland Unit 27/35, IDA Industrial Park, Cork Road, Waterford, Irska
• The dose indicator tells you how many doses (inhalations) are left in your inhaler, starting with 60 inhalations when it is full. 
• Kazalnik odmerkov kaže, koliko odmerkov (inhalacij) je še v inhalatorju.
Each delivered dose (the dose that leaves the mouthpiece of the Spiromax) contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate. 
En dovedeni odmerek (odmerek, ki pride iz ustnika Spiromax) vsebuje 160 mikrogramov budezonida in 4,5 mikrogramov formoterolijevega fumarata dihidrata.
Each delivered (inhaled) dose contains 320 micrograms of budesonide and 9 micrograms of formoterol fumarate dihydrate. 
En dovedeni (inhalirani) odmerek vsebuje 320 mikrogramov budezonida in 9 mikrogramov formoterolijevega fumarata dihidrata.
Budesonide/Formoterol Teva 160 mcg/4.5 mcg inhalation powder budesonide/formoterol fumarate dihydrate 
Budezonid/formoterol Teva 160 mcg/4,5 mcg prašek za inhaliranje budezonid/formoterolijev fumarat dihidrat za inhaliranje
Fertility 
FOLIJA
Front panel: This delivered dose is equivalent to a metered dose of 400 micrograms of budesonide and 12 micrograms of formoterol fumarate dihydrate. 
Sprednja ploskev: Ta dovedeni odmerek je enakovreden odmerjenemu odmerku 400 mikrogramov budezonida in 12 mikrogramov formoterolijevega fumarata dihidrata.
You should speak to your doctor if you are concerned as to whether you should continue to use Budesonide/Formoterol Teva. 
Svojemu zdravniku morate povedati, če imate med jemanjem zdravila Budezonid/formoterol Teva.
Date of latest renewal: 
DRUGI PODATKI Začetek:
If you get any side effects, talk to your doctor,pharmacist or nurse. 
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Budesonide/Formoterol Teva 320 micrograms/9 micrograms inhalation powder budesonide/formoterol fumarate dihydrate 
Budezonid/formoterol Teva 320 mikrogramov/9 mikrogramov prašek za inhaliranje budezonid/formoterolijev fumarat dihidrat za inhaliranje
Budesonide/Formoterol Teva 160 micrograms / 4.5 micrograms inhalation powder budesonide/ formoterol fumarate dihydrate 
Budezonid/formoterol Teva 160 mikrogramov/4,5 mikrogramov prašek za inhaliranje budezonid/formoterolijev fumarat dihidrat za inhaliranje
• Disturbed sleep. 
• motnje spanja,
Inhalation powder. 
• mišični krči.
- in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. 
- pri bolnikih, pri katerih bolezni ne moremo ustrezno nadzorovati z inhalacijskimi kortikosteroidi ter kratkodelujočimi inhalacijskimi agonisti adrenergičnih receptorjev β2, ki so predpisani za uporabo po potrebi.
Budesonide/Formoterol Teva is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age. 
Zdravilo Budezonid/formoterol Teva ni indicirano za uporabo pri otrocih, starih 12 let ali manj, ali mladostnikih, starih od 13 do 17 let.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with Budesonide/Formoterol Teva . 
Če po uvedbi zdravila Budezonid/formoterol Teva simptomi astme niso nadzorovani ali se poslabšajo, naj bolniki nadaljujejo z zdravljenjem in poiščejo zdravniško pomoč.
Package leaflet: Information for the patient Budesonide/Formoterol Teva 160 micrograms/4.5 micrograms, inhalation powder 
Navodilo za uporabo Budezonid/formoterol Teva 160 mikrogramov/4,5 mikrogramov, prašek za inhaliranje
Adults (18 years and older): 1 inhalation twice daily 
Odrasli (18 let in več): 1 vdih dvakrat na dan
Adults (18 years and older): • 1 inhalation twice a day. 
Odrasli (18 let in več): • 1 vdih dvakrat na dan.
Package leaflet: Information for the patient Budesonide/Formoterol Teva 320 micrograms/9 micrograms, inhalation powder 
Navodilo za uporabo Budezonid/formoterol Teva 320 mikrogramov/9 mikrogramov, prašek za inhaliranje
• Feeling dizzy. 
• omotica,
Adults (18 years and older): 1-2 inhalations twice daily. 
Odrasli (18 let in več): 1-2 vdiha dvakrat na dan.
What you need to know before you use Budesonide/Formoterol Teva (page 5) 3. 
Kaj je zdravilo Budezonid/formoterol Teva in za kaj ga uporabljamo (stran 3) Kaj morate vedeti, preden boste uporabili zdravilo Budezonid/formoterol Teva (stran 5) Kako uporabljati zdravilo Budezonid/formoterol Teva (stran 8) Možni neželeni učinki (stran 16)
If the patient experiences paradoxical bronchopasm Budesonide/Formoterol Teva should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. 
V tem primeru je treba zdravljenje z zdravilom Budezonid/formoterol Teva takoj prekiniti, režim zdravljenja ponovno ovrednotiti in po potrebi uvesti drugo vrsto zdravljenja.
Palpitations 
INHALATOR
Adults (18 years and older): 1 inhalation twice daily. 
Odrasli (18 let in več): 1 vdih dvakrat na dan.
Adults (18 years and older): 2 inhalations twice a day. 
Odrasli (18 let in več): 2 vdiha dvakrat na dan.
Advising the patient to rinse the mouth out with water after each dose will minimise the risk. 
Tveganje za ta neželeni učinek lahko zmanjšate, če bolniku naročite, naj si po vsakem odmerku spere usta z vodo.
• Low levels of potassium in your blood. 
• nizka koncentracija kalija v krvi, • neenakomerno bitje srca.
CLINICAL PARTICULARS 
Posebne skupine bolnikov:
Lactose monohydrate. 
6.1 Seznam pomožnih snovi laktoza monohidrat
Paradoxical bronchospasm 
Delovanje nadledvične žleze
Talk to your doctor, pharmacist or nurse before taking Budesonide/Formoterol Teva if 
Pred začetkom uporabe zdravila Budezonid/formoterol Teva se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
13 February 2012 
13. februar 2012
The European Commission issued a decision on 13 February 2012. 
Evropska komisija je izdala odločbo dne 13. februarja 2012.
Outcome of a procedure under Article 107 of Directive 2001/ 
Izid postopka v skladu s členom 107 Direktive 2001/83/ES
• Patients who have any questions should speak to their doctor or pharmacist. 
• Bolniki, ki imajo kakršna koli vprašanja, naj se pogovorijo s svojim zdravnikom ali farmacevtom.
Buflomedil is authorised in Austria, Belgium, Cyprus, France, Germany Luxembourg, the Netherlands, Poland, Portugal and Spain, under the invented na trade names. 
Buflomedil je odobren v Avstriji, Belgiji, na Cipru, v Franciji, Nemčiji, Grčiji, Italiji, Luksemburgu, na Nizozemskem, Poljskem, Portugalskem in v Španiji pod izmišljenim imenom Loftyl in drugimi tržnimi imeni.
Questions and answers on the suspension of buflomedil-containing medicines EMA/CHMP/560863/2011 rev1 
Vprašanja in odgovori o začasnem umiku zdravil, ki vsebujejo buflomedil EMA/CHMP/560863/2011 rev1
What is buflomedil? 
Kaj je buflomedil?
Questions and answers on the suspension of buflomedilcontaining medicines 
Vprašanja in odgovori o začasnem umiku zdravil, ki vsebujejo buflomedil
Buflomedil-containing medicines have been authorised in the EU since the 1970s vi procedures. 
Zdravila, ki vsebujejo buflomedil, so bila v EU odobrena z nacionalnimi postopki od sedemdesetih let prejšnjega stoletja dalje.
These side effects mainly occurred in elderly patients or in patients with kidney problems who did not receive the appropriately reduced dose and whose kidney function was not suitably monitored. 
Ti stranski učinki so se pojavljali predvsem pri starejših bolnikih z ledvičnimi težavami, ki niso prejemali ustrezno zmanjšanega odmerka in pri katerih delovanja ledvic niso ustrezno spremljali.
• Patients currently using buflomedil-containing medicines should speak to their doctor to review their treatment. 
• Bolniki, ki trenutno uporabljajo zdravila, ki vsebujejo buflomedil, naj se posvetujejo s svojim zdravnikom, ki bo pregledal njihovo zdravljenje.
Why was buflomedil reviewed? 
Zakaj je bilo zdravilo buflomedil pregledano?
In February 2011, the French medicines regulatory agency suspended the marketing authorisations for buflomedil-containing medicines because of serious and sometimes fatal side effects seen with these medicines. 
Februarja 2011 je francoska regulatorna agencija za zdravila začasno umaknila dovoljenja za promet z zdravili, ki vsebujejo buflomedil, zaradi resnih in včasih usodnih neželenih učinkov, ki so jih opazili pri teh zdravilih.
These included neurological disorders such as convulsions and status epilepticus (a dangerous condition where the brain is in a persistent state of seizure), and cardiac disorders such as accelerated heart rate and cardiac arrest. 
Ti so vključevali nevrološke motnje, kakršne so konvulzije in status epilepticus (nevarno stanje, pri katerem so možgani v stanju nenehnega napada) in srčne bolezni, kot sta povišan srčni utrip in srčni zastoj.
These include managing underlying health problems which can increase the risk of PAOD, such as diabetes, high cholesterol, high blood pressure as well as smoking. 
Le-ta vključujejo urejanje osnovnih zdravstvenih težav, ki lahko povečajo tveganje za pojav periferne arterijske okluzivne bolezni, kakršne so sladkorna bolezen, visok holesterol, visok krvni tlak in kajenje.
France had previously taken d not been sufficient to e 107, France informed the CHMP of its latest action to suspend the marketing mmittee could prepare an opinion on whether the marketing authorisations for products containing buflomedil should be maintained, changed, suspended or 
Francija je v skladu s členom 107 obvestila odbor CHMP o svojem najnovejšem ukrepu za začasni umik dovoljenj za promet v Franciji, da bi odbor lahko pripravil mnenje o tem, ali je treba dovoljenja za promet z zdravili, ki vsebujejo buflomedil, v vsej EU ohraniti, spremeniti, preklicati ali umakniti.
The European Medicines Agency has completed a review of the safety and effectiveness of buflomedilboth oral and injectable, due to serious side effects seen with buflomedil. 
Evropska agencija za zdravila je opravila pregled varnosti in učinkovitosti zdravil, ki vsebujejo buflomedil, v peroralnih in injekcijskih pripravkih, zaradi resnih neželenih učinkov, ki so jih opazili v zvezi z buflomedilom.
Based on the evaluation of the currently available data and the scientific disc Committee, the CHMP concluded that the benefits of bufl their risks, and recommended that all marketing authorisations for medicines co should be suspe 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v odboru je CHMP zaključil, da koristi zdravil, ki vsebujejo buflomedil, ne odtehtajo z njim povezanih tveganj, in priporočil, da se vsa dovoljenja za promet s temi zdravili v vsej EU začasno prekličejo.
The CHMP noted that there was a risk of seriou buflomedil is used normally, due to the small difference between the treatin can harm elderly patients or people with certain conditions such as kidney problem common in patients with PAOD. 
Odbor CHMP je ugotovil, da obstaja tveganje za resne nevrološke in srčne neželene učinke pri bolnikih ob običajni uporabi buflomedila zaradi majhne razlike med odmerkom zdravljenja in odmerkom, ki lahko starejšim bolnikom ali osebam z določenimi boleznimi, kakršne so npr. ledvične težave, ki so pri bolnikih s periferno arterijsko okluzivno boleznijo pogoste, škoduje.
In spite of measures put in place by regulatory authori been shown to have a limited benefit for patients, measured in term studies also had a number of methodological weaknesses. 
Odbor CHMP je ugotovil tudi, da je bila za zdravilo dokazana le omejena korist za bolnike, izmerjena v smislu prehojene razdalje, ter da so imele študije številne metodološke slabosti.
2011, as well as information requested fro and the published literature, as well as from poison control centres in Europe on cases of severe poisoning with buflomedil. 
Vključeni so bili tudi podatki iz kliničnih preskušanj z buflomedilom, nadzor v obdobju trženja in objavljena literatura, kakor tudi podatki iz centrov za zastrupitve v Evropi o primerih hudih zastrupitev z buflomedilom.
Agency's Committee for Medicinal Products for Human Use (CHMP) concluded buflomedil do not outweigh its risks, and has recommended that all marketing au medicines containing buflomedil should be suspended throughout the European 
Odbor za zdravila za uporabo v humani medicini (CHMP) agencije EMA je ugotovil, da koristi buflomedila ne odtehtajo z njim povezanih tveganj, in priporočil začasni umik vseh dovoljenj za promet z zdravili, ki vsebujejo buflomedil, v vsej Evropski uniji (EU).
Buflomedil is available in the form of tablets, an oral solution or a s 
Buflomedil je na voljo v obliki tablet, peroralne raztopine ali raztopine za injiciranje.
Buflomedil is a vasoactive agent, a medicine which has an effect on blood c increases the blood flow to the brain and other parts of the body by widening the bl used to treat the symptoms of peripheral arterial occlusive disease (PAOD), a cond the legs. 
Buflomedil poveča pretok krvi v možgane in druge dele telesa, tako da razširi krvne žile.
Buflomedil is used in pat pain when walking relatively short distances. 
Buflomedil se uporablja pri bolnikih s periferno arterijsko okluzivno boleznijo tipa II, kar pomeni, da imajo hude bolečine, že če prehodijo razmeroma kratko razdaljo.
The CHMP considered the benefit-risk assessments previously carried out, including by France in 2010 
Odbor CHMP je upošteval predhodno izvedene ocene razmerja med tveganji in koristmi, vključno z oceno, ki je bila izvedena v Franciji v letih 2010 in 2011, kakor tudi informacije, pridobljene od družb, ki v EU tržijo zdravila, ki vsebujejo buflomedil.
• Doctors should stop prescribing buflomedil and co 
• Zdravniki naj prenehajo predpisovati buflomedil in razmislijo o alternativnih možnostih zdravljenja.
Buflomedil can build up in the body and there is only a small difference between the treating dose and the dose that can harm certain patients, such as those with 
Buflomedil se v telesu lahko kopiči, razlika med odmerkom zdravljenja in
These included changes to the packaging and p recommendations on adjusting the dose for patients with kidney problems and restr medicines' use in certain patients (for instance pati such measures in 1998 and 2006, but concluded in February 2011 that these ha prevent serious side effects from occurring in France. 
Ti ukrepi so vključevali spremembe podatkov na embalaži in informacij o zdravilu, priporočila za prilagoditev odmerka za bolnike z ledvičnimi težavami in omejitve pri uporabi zdravila za določene bolnike (na primer bolnike z epilepsijo).
Measures to minimise the risks with buflomedil had already been taken in som where the medicine is marketed. 
V nekaterih državah članicah, ki zdravilo tržijo, so že sprejeli ukrepe za zmanjšanje tveganj, povezanih z buflomedilom.
Patients with PAOD are likely to have kidney problems due to the nature of the e of the Member States roduct information, ictions on the ents with epilepsy). 
Bolniki s periferno arterijsko okluzivno boleznijo utegnejo imeti ledvične težave zaradi narave bolezni.
It is ition where the body's large arteries become obstructed causing symptoms such as pain and weakness, particularly in ients with stage II PAOD, which means that they experience severe a national , Greece, Italy, me Loftyl and other olution for injection. 
Uporablja se za zdravljenje simptomov periferne arterijske okluzivne bolezni, stanja, pri katerem je pretok skozi velike arterije telesa oviran, kar povzroči simptome, kakršna sta bolečina in šibkost, še posebej v nogah.
No specific carcinogenicity studies were performed. 
Posebne študije kancerogenosti niso bile izvedene.
The product information may be subsequently updated by the Member State competent authorities, in liaison with the reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC. 
Informacije o zdravilu se lahko naknadno posodobijo s strani pristojnega organa države članice v povezavi z referenčno državo članico, kot je primerno v skladu s postopki opisanimi v poglavju 4 pod naslovom III Direktive 2001/83/ES.
To date, no data are available on humans. 
Za človeka za zdaj ni podatkov.
The data on this effect remains controversial (see Sections 4.4 and 5.1). 
Podatki o tem učinku ostajajo nasprotujoči (glejte poglavji 4.4 in 5.1).
The frequencies classification follows the convention: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000) and Very rare (<1/10,000). 
Razvrstitev pogostnosti upošteva naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
Additionally, there are important individual variations with regards to the onset and duration of action. 
Poleg tega so pomembne razlike med posamezniki tudi glede začetka in trajanja delovanja.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
Neuporabljeno zdravilo ali odpadni material je treba odvreči v skladu z lokalnimi zahtevami.
In severe cases, respiratory arrest may occur. 
V hudih primerih lahko pride do zastoja dihanja.
This leaflet was last revised in {month YYYY}. 
Navodilo je bilo nazadnje revidirano dne {mesec YYYY}
The higher risk of bleeding is more associated with the procedure, rather than with the medicine. 
Večje tveganje za krvavitve je bolj povezano s posegom kot z zdravilom.
In the absence of compatibility studies, this medicinal product must not be mixed with any other medicinal products. 
Ker kompatibilnostne študije niso bile izvedene, se tega zdravila ne sme mešati z nobenim drugim zdravilom.
Frequency “not known”: “not known (cannot be estimated from the available data)”. 
Pogostnost “neznana”: “neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov)”.
Elderly patients: Dosages should be reduced in elderly patients (due to lack of clinical data). 
Starejši bolniki: Pri starejših bolnikih je treba zmanjšati odmerek (zaradi pomanjkanja kliničnih podatkov).
Limited data of overdose are available. 
Na voljo so omejeni podatki o prevelikem odmerjanju.
The injection rate shall be very slow (1 ml/min). 
Hitrost injiciranja naj bo zelo majhna (1 ml/min).
This property could be beneficial when the use of vasoconstrictor is contraindicated. 
Ta lastnost je lahko prednost, kadar je uporaba vazokonstriktorja kontraindicirana.
Serious adverse experiences are generally systemic. 
Resni neželeni učinki so praviloma sistemski.
For poorly controlled epileptic patients, see section 4.3. 
Za bolnike s slabo urejeno epilepsijo glejte poglavje 4.3.
- Hypotension. 
- hipotenzija.
However, considering the lack of data for mepivacaine, a risk to the newborns/infants cannot be excluded. 
A ker podatkov za mepivakain ni, tveganja za novorojenčke/dojenčke ni mogoče izključiti.
The plasma elimination half-life is 2 hours for adults. 
Plazemski razpolovni čas izločanja je 2 uri pri odraslem.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine. 
O neželenih učinkih lahko poročate prek nacionalnega sistema poročanja navedenega v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
The maximum plasma level of mepivacaine is achieved approximately after 30-60 minutes. 
Največja raven mepivakaina v plazmi je dosežena po približno 30 - 60 minutah.
Do not use this medicine if you notice that the solution is not clear and colourless. 
Ne uporabljajte tega zdravila, če opazite, da raztopina ni bistra in brezbarvna.
Caution should be taken in all patients with porphyria, as this medicinal product may trigger porphyria. 
Previdnost je potrebna pri vseh bolnikih s porfirijo, saj lahko to zdravilo izzove porfirijo.
As patients possess different body weights, each patient possess a different maximum allowed quantity of mepivacaine that can tolerate. 
Ker imajo bolniki različne telesne mase, ima vsak bolnik drugačno največjo dovoljeno količino mepivakaina, ki jo lahko prenaša.
Clearance of amides is dependent on hepatic blood flow. 
Očistek amidov je odvisen od hepatičnega krvnega pretoka.
However, the absence of blood in the syringe does not guarantee that intravascular injection has been avoided. 
Vseeno pa odsotnost krvi v injekcijski brizgi ne zagotavlja, da ni prišlo do intravaskularnega injiciranja.
They will determine the appropriate dose taking into account the procedure, your age, your weight and your general health. 
Oni bodo določili ustrezni odmerek z upoštevanjem posega, vaše starosti, telesne mase in splošnega zdravstvenega stanja.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila prek nacionalnega sistema poročanja navedenega v Dodatku V.
The duration of the local anaesthetic is unrelated to the half-life as its action is terminated when the drug is removed from the receptor. 
Trajanje delovanja lokalnega anestetika ni povezano z razpolovnim časom, saj se njegovo delovanje zaključi, ko se zdravilo odstrani z receptorja.
H2 antihistaminics (cimetidine) 
Antihistaminiki H2 (cimetidin)
Recommended therapeutic dose: 
Priporočeni terapevtski odmerek:
This medicine is given as an injection in the oral cavity. 
To zdravilo se da kot injekcija v ustno votlino.
Very rare Hypertension Not known Vasodilatation Local/ Regional hyperaemia 
zelo redki hipertenzija neznana vazodilatacija lokalna/regionalna hiperemija
Elimination can be accelerated by acidifying the urine. 
Izločanje se lahko pospeši z nakisanjem urina.
The total dose of administered mepivacaine should not exceed the maximum recommended dose. 
Celokupni uporabljeni odmerek mepivakaina ne sme preseči največjega priporočenega odmerka.
In case a reinjection is required, patient should be monitored, to identify any sign of relative overdose. 
V primeru, da je potrebno dodatno injiciranje, je treba bolnika nadzirati, da bi se ugotovilo kakršen koli znak relativnega prekomernega odmerjanja.
Unused solution must be discarded. 
Neporabljeno raztopino je treba zavreči.
X is a local anaesthetic, which numbs a particular region to prevent or minimize pain. 
Zdravilo X je lokalni anestetik, ki omrtviči določeno področje za preprečitev ali zmanjšanje bolečine.
The cartridges should under no circumstance be dipped into any solution whatsoever. 
Vložka pod nobenimi pogoji ne smemo potopiti v kakršno koli raztopino.